Clinical-stage stem cell group ReNeuron surged on Tuesday after saying that the Data Safety Monitoring Board gave a favourable recommendation to proceed to the with a higher dose of its ReN001 stem cell therapy in a clinical trial. 'This represents a further important milestone for the study as we make our plans for a subsequent Phase II clinical trial application with ReNeuron's ReN001 cell-based treatment for stroke disability,' said ReNeuron's Chief Executive Michael Hunt. [14 Aug '12]
Clean energy products company Acta has said it is pleased with Taiwan's Ministry of Economic Affairs decision to approve the safety and reliability standards for fuel cell scooters and motorcycles, meaning they are now ready for mass production. Acta said it believes that the release of road standards for fuel cell motorcycles and scooters will help to accelerate the introduction and adoption of these vehicles together with the refuelling kiosk within tourist destinations and [2 Aug '12]
Mining firm Noventa says that operations have suffered from a "plague" of beetles as a result of tropical storms which have hit the firm's Marropino site in Mozambique over the past 10 days. The Rove Beetle is very poisonous and around 30% of the workforce at Marropino have been affected by the severe skin and eye irritations caused by coming into contact with the insects. The firm was keen to emphasise that an effective treatment has now been administered and a pesticide is being sprayed to erradicate the infestation. Progress at Marropino has been delayed and is set to start in March, a delay of around a month. Shares dropped 2.78% to 17.5p. [2 Feb '12]
Scam-hit Healthcare Locums (HCL) hoped to soothe investor jitters by saying the majority of its UK operations are sound and it is considering refinancing opportunities to stabilise its capital structure, but the on-going probe has cast a shadow over the validity of its prior year results. [29 Jun '11]
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.